Phase 1 B-cell Non Hodgkin Lymphoma Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1Phase 2
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Chronic Lymphocytic LeukemiaB-cell Non Hodgkin Lymphoma
Medical University of South Carolina27 enrolled1 locationNCT05702853
Recruiting
Phase 1
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Sanofi96 enrolled16 locationsNCT06392477
Recruiting
Phase 1
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University24 enrolled1 locationNCT06707259
Recruiting
Phase 1
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT05472558
Recruiting
Phase 1
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc.186 enrolled1 locationNCT06725524
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
B-cell Non Hodgkin Lymphoma
AbClon82 enrolled1 locationNCT05338931